Drug Labeling With Tiered Evidence Levels Eyed As Fix For Off-Label Promotion
This article was originally published in The Pink Sheet Daily
Working group convened by Duke-Margolis Center for Health Policy lays out several policy proposals aimed at addressing current regulatory challenges with communication about unapproved uses of existing products.
You may also be interested in...
Agency originally said it would issue a draft guidance on industry’s interactions with formulary committees in 2014, but CDER Director Woodcock says “extremely contentious” issues have slowed progress.
Agency grants two citizen petitions from a coalition of pharma companies requesting greater clarity from FDA, but whether the forthcoming guidances will satisfy industry remains an open question.
Seattle Genetics holds the award for fastest supplemental approval (11 days) and fastest new molecular entity approval (119 days) under the US FDA's RTOR program, according to the Pink Sheet's Performance Tracker.